Nura Bio

Nura Bio is developing neuroprotective medicines for the treatment of neurological diseases. Axon degeneration is an early and catastrophic event in neurological diseases as regeneration is inefficient. Nura’s approach is to target the fundamental pathways underlying neurological diseases including axon degeneration and neuroimmune regulation to preserve neuronal integrity. Nura has identified SARM1 as a promising molecular target since the protein is an axon-intrinsic metabolic sensor and regulator. Nura is currently developing small molecule inhibitors of SARM1 for the treatment of peripheral, central and ocular nervous system disorders. In addition, Nura is identifying ways to restore the function of the neuron-glia axis to improve the nervous system’s immune response.

Jobs: